Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations

Lancet

Volumn 355, Issue 9210, 2000, Pages 1126-1130

  Troughton, Richard W ^a   Frampton, Christopher M ^a   Yandle, Timothy G ^a   Espiner, Eric A ^a   Nicholls, M Gary ^a   Richards, A Mark ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FUROSEMIDE; ISOSORBIDE MONONITRATE; LOOP DIURETIC AGENT; METOLAZONE; SPIRONOLACTONE;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SYSTOLE; THEORY;

EID: 0034176934     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02060-2     Document Type: Article

References (29)

1. Remme W.J. Therapeutic strategies and neurohormonal control in heart failure. Eur Heart J. 15:1994;129-138. (suppl D).
2. Cleland J.G., Swedberg K., Poole-Wilson P.A. Successes and failures of current treatment of heart failure. Lancet. 352:1998;SI19-28.
3. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1987;1429-1435.
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
5. Pitt B., Zannad F., Remme W.J.et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341:1999;709-717.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet. 353:1999;9-13.
7. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007.
8. Kornowski R., Zeeli D., Averbuch M.et al. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure. Am Heart J. 129:1995;762-766.
9. Rich M.W., Beckham V., Wittenberg C., Leven C.L., Freedland K.E., Carney R.M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 333:1995;1190-1195.
10. Stevenson L.W., Dracup K.A., Tillisch J.H. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol. 63:1989;461-464.
11. Steimle A.E., Stevenson L.W., Chelimsky-Fallick C.et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 96:1997;1165-1172.
12. Reis S.E., Holubkov R., Edmundowicz D.et al. Treatment of patients admitted to the hospital with congestive heart failure. specialty-related disparities in practice patterns and outcomes J Am Coll Cardiol. 30:1997;733-738.
13. van Veldhuisen D.J., Charlesworth A., Crijns H.J., Lie K.I., Hampton J.R. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J. 20:1999;666-672.
14. Cohn J.N., Levine T.B., Olivari M.T.et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
15. Francis G.S., Cohn J.N., Johnson G., Rector T.S., Goldman S., Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 87:1993;VI 40-48.
16. Schrier R.W., Abraham W.T. Mechanisms of disease. hormones and hemodynamics in heart failure N Engl J Med. 341:1999;577-585.
17. Yasue H., Yoshimura M., Sumida H.et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
18. Hunt P.J., Espiner E.A., Nicholls M.G., Richards A.M., Yandle T.G. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides. 18:1997;1475-1481.
19. Richards A.M., Nicholls M.G., Yandle T.G.et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction Circulation. 97:1998;1921-1929.
20. Richards A.M., Nicholls M.G., Yandle T.G.et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart. 81:1999;114-120.
21. Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium. effect of stretching Endocrinology. 132:1993;1961-1970.
22. Richards A.M., Crozier I.G., Yandle T.G., Espiner E.A., Ikram H., Nicholls M.G. Brain natriuretic factor. regional plasma concentrations and correlations with haemodynamic state in cardiac disease Br Heart J. 69:1993;414-417.
23. Magga J., Vuolteenaho O., Tokola H., Marttila M., Ruskoaho H. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med. 30:1998;39-45. (suppl 1).
24. Davis M., Espiner E., Richards G.et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444.
25. Murdoch D.R., McDonagh T.A., Byrne J.et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration. randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy Am Heart J. 138:1999;1126-1132.
26. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 22:1993;6A-13A.
27. Doughty R., Yee T., Sharpe N., MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91. N Z Med J. 108:1995;473-475.
28. Cohn J.N., Ziesche S., Smith R.et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III - Vasodilator-Heart Failure Trial (V-HeFT) Study Group Circulation. 96:1997;856-863.
29. Domanski M.J., Exner D.V., Borkowf C.B., Geller N.L., Rosenberg Y., Pfeffer M.A. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. a meta-analysis of randomized clinical trials J Am Coll Cardiol. 33:1999;598-604.